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ARTICLE
Cross-ethnic meta-analysis identiﬁes association of
the GPX3-TNIP1 locus with amyotrophic lateral
sclerosis
Beben Benyamin et al.#
Cross-ethnic genetic studies can leverage power from differences in disease epidemiology
and population-speciﬁc genetic architecture. In particular, the differences in linkage dis-
equilibrium and allele frequency patterns across ethnic groups may increase gene-mapping
resolution. Here we use cross-ethnic genetic data in sporadic amyotrophic lateral sclerosis
(ALS), an adult-onset, rapidly progressing neurodegenerative disease. We report analyses of
novel genome-wide association study data of 1,234 ALS cases and 2,850 controls. We ﬁnd a
signiﬁcant association of rs10463311 spanning GPX3-TNIP1 with ALS (p= 1.3 × 10−8), with
replication support from two independent Australian samples (combined 576 cases and 683
controls, p= 1.7 × 10−3). Both GPX3 and TNIP1 interact with other known ALS genes (SOD1
and OPTN, respectively). In addition, GGNBP2 was identiﬁed using gene-based analysis and
summary statistics-based Mendelian randomization analysis, although further replication is
needed to conﬁrm this result. Our results increase our understanding of genetic aetiology of
ALS.
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For people of European ancestry, the lifetime risk of amyo-trophic lateral sclerosis (ALS) is 0.3–0.5%1, 2, with peak ageof onset of 58–63 years3, and median survival of 2–4 years4.
Investigations of families with multiple affected individuals have
led to the identiﬁcation of mutations that segregate with disease
in a number of genes, including SOD1, C9orf72, TARDBP, FUS
and TBK15, 6. However, about 90% of cases5 (‘sporadic ALS’
(sALS)) present with sparse or no family history. Nonetheless,
genome-wide association studies (GWAS) have provided direct
evidence of a genetic contribution to sALS, with estimates that
~8.5%7 of variance in liability is tagged by common single-
nucleotide polymorphisms (SNPs). Currently, only a small
proportion of this variation (0.2% of variance in liability)7 is
accounted for by the six common loci (C9orf72, UNC13A,
SARM1, MOBP, SCFD1, C21orf2) identiﬁed as signiﬁcant based
on association analysis of 12,577 cases and 23,475 controls7. The
SNP-heritability estimate implies that more risk loci will be
detected with increasing sample size, as found for other complex
genetic diseases8. Whole-exome sequencing (WES) studies,
designed to identify genes enriched for rare variants, have also
been conducted for sALS. The largest study, comprising 2,874
cases and 6,405 controls, identiﬁed TBK1 as a novel ALS
risk gene6, with GWAS support for association of common loci
(p= 6.6 × 10−8)7. Rare variant burden analysis in a WES of 1,022
index familial cases identiﬁed p.Arg261His in NEK1 as an ALS
associated variant, and follow-up in large samples suggest that
this variant together with NEK1 loss of function mutations
account for ~3% of ALS cases9.
To date, the largest genetic studies for ALS are in the subjects
of European ancestry, but common variants associated with
disease are likely to be ancient and shared across ethnicities.
Given sufﬁcient power, cross-ethnic genetic studies can aid ﬁne
mapping of disease loci, exploiting differences in allele frequency
and linkage disequilibrium (LD). In China, the lifetime risk of
ALS is estimated to be lower (0.1%)1 and its mean age of onset
is estimated to be a few years earlier than in Europe4, 10.
High penetrance mutations in known ALS genes identiﬁed
in Europeans have been detected in Chinese cases11, but the
frequency of the C9orf72 expansion is much lower (0.3%)12
than in Europeans (frequency 7%)5, and it may have arisen on a
different haplotype background12.
In a cross-ethnic meta-analysis of the largest GWAS for ALS in
Europeans7, together with a new Chinese data set, we identify
the GPX3-TNIP1 locus to be signiﬁcantly associated with ALS
(p= 1.3 × 10−8). This association is replicated in two independent
Australian cohorts with a combined p-value of 1.7 × 10−3.
Previous studies indicate functional relevance of both GPX3 and
TNIP113–18. The identiﬁcation of this locus contributes to a better
understanding of the genetic aetiology of ALS.
Results
Genome-wide association analysis. We conduct a genome-wide
(GW) association analysis in a Chinese sample of 1,234 sALS
cases and 2,850 controls (Supplementary Table 1 and Supple-
mentary Figs 1−3). The genomic inﬂation factor λGC of 1.02 and
λ1000 of 1.01 showed no evidence for inﬂation in test statistics.
The combined effects of all common genetic variants on ALS
liability (SNP-heritability) estimated from the Chinese GWAS
data is 15.1% (SE): 4%; p= 9.5 × 10−5) using GCTA-GREML19
and 15.0% (SE: 3.5%) using LD score regression20 (intercept 1.0,
which also shows no evidence of population stratiﬁcation).
Given the SE, these estimates are not different from the estimate
of 8.5% (SE 0.5%) from European data7. Partitioning of the
SNP-heritability by chromosome showed a signiﬁcant positive
correlation with chromosome length (Supplementary Fig. 4a)
consistent with a polygenic architecture. Based on minor allele
frequency (MAF) bin, the SNP-heritability was attributed to SNPs
across the MAF range, but SEs per bin were large (Supplementary
Fig. 4b); similar analyses based on European data suggested
that less common SNPs tagged more variation than other MAF
classes7.
No individual SNPs passed the GW signiﬁcant p value
threshold of 5 × 10−8, and none of the signiﬁcant SNPs reported
in the European7 GWAS replicated in our samples (p> 0.05). We
also checked for the associations of two GW signiﬁcant SNPs in
previous GWAS of Chinese cohort of ALS patients21. However,
we could not replicate the association in that study. We note that
despite evidence for population stratiﬁcation, principal compo-
nents derived from SNP data of the previous study were not
included as covariates in their association analysis. The p values
for rs6703183 and rs8141797 are 0.07 and 0.12 in our Chinese
samples and 0.66 and 0.94 in European GWAS results,
respectively. Direction of effect sign tests (Supplementary Table 2)
and polygenic risk scoring analyses (Supplementary Fig. 5)
provided no conclusive evidence of shared risk loci (Nagelkerke’s
R2 = 0.002; p= 0.01). These results are not unexpected given the
size of our sample and effect sizes estimated in Europeans. The
Chinese GWAS sample had 80% power to identify common
genetic variants of genotype relative risk of 1.4 and 1.8 for risk
allele frequency of 0.2 and 0.05, respectively, at the GW threshold
of signiﬁcance p= 5 × 10−8.
Meta-analysis. Meta-analysis of our results with those of the
European7 GWAS identiﬁed a new GW signiﬁcant locus at
chromosome 5p33.1 (rs10463311, risk allele C, odds ratio (OR)
1.11 95% conﬁdence interval (CI): 1.06–1.14, plogistic= 2.9 × 10−8;
plmm= 1.3 × 10−8) spanning the genes GPX3 and TNIP1 (Figs. 1
and 2; Table 1; Supplementary Data 1) for which the risk allele is
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Fig. 1Manhattan plot of the meta-analysis between European and Chinese GWAS revealed a novel locus, GPX3-TNIP1 (red). Loci previously identiﬁed in the
largest European GWAS are presented in blue. The p values are from the linear mixed model
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more common in Chinese than in Europeans (0.46 vs. 0.25). The
association result was replicated in an independent Australian
sample (145 cases, 116 controls, OR= 1.66; 95% CI: 1.16–2.38;
p= 5.8 × 10−3) and had the same direction of effect in a second
Australian sample (431 cases, 567 controls, OR= 1.22; 95% CI:
1.00–1.48; p= 6.2 × 10−2), giving a combined replication OR of
1.32 (95% CI: 1.11–1.58; p= 1.7 × 10−3) (Table 1).
Functional relevance of GPX3 and TNIP1. Both GPX3 and
TNIP1 are genes that could have functional relevance for ALS.
The protein glutathione peroxidase 3 (GPX3), is an antioxidant
molecule functionally related to superoxide dismutase 1
(SOD1)13; many SOD1 single-nucleotide variants are pathogenic
for ALS. In a mass spectrometric screen of sera of SOD1H46R
rats compared to their wild-type (WT) controls in the pre-
symptomatic stage (12 weeks of age) of ALS, Gpx3 was
detected as one of the two signiﬁcant results (1.3-fold increase in
expression)14. In the same study, Gpx3 expression was
signiﬁcantly lower (0.74 fold, p= 0.009) compared to WT
controls by disease end stage, a ﬁnding which was replicated in
blood sera of sporadic ALS cases (n= 18) and controls (n= 35)
(GPX3 0.41-fold lower, p= 0.008)14. Both GPX3 and TNIP1 are
functionally associated with NF-κB, the master regulator of
inﬂammation17, 19, with upregulation of NF-κB associated with
death of motor neurones15. Protein–protein interaction analysis18
links GPX3 to SOD1 and TNIP1 to OPTN, and OPTN also
harbours mutations associated with familial ALS5. TNIP1 is
associated with a wide range of immune disorders22, 23, although
our most associated SNP (rs10463311) is not in LD with
speciﬁc SNPs associated with these disorders24. We investigated
differential expression of GPX3 and TNIP1 between ALS patients
and controls, but given small sample sizes, the results were not
conclusive (Supplementary Note 1, Supplementary Table 3,
Supplementary Fig. 6). In a pleiotropy informed analysis25
applied to the European GWAS summary statistics7, rs10463311
was identiﬁed as an ALS-associated SNP, providing additional,
albeit not fully independent, support for this locus.
Meta analysis
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Fig. 2 Regional ALS association plot of the GPX3-TNIP1 locus from the meta-analysis results created using LocusZoom44. From the meta-analysis,
rs10463311 is the SNP with the strongest association with ALS (p= 1.3 × 10−8). This SNP is replicated in two independent Australian cohorts with combined
p= 1.7 × 10−3
Table 1 Association analysis results between rs10463311 spanning GPX3-TNIP1 and ALS across cohorts
Cohort N cases N cont Freq cases Freq cont OR 95% CI plogistic
European2 12,577 23,475 0.27 0.24 1.11 1.07–1.15 8.5 × 10−7
Chinese 1,234 2,850 0.48 0.45 1.14 1.03–1.26 6.8 × 10−3
Meta-analysis 1.11 1.07–1.15 2.4 × 10−8
Replication
Australian #1 145 116 0.32 0.22 1.66 1.16–2.38 5.8 × 10−3
Australian #2 431 567 0.27 0.24 1.22 1.00–1.48 6.2 × 10−2
Combined 576 683 0.29 0.23 1.32 1.11–1.58 1.7 × 10−3
Cont, control; OR, odds ratio. The allele frequency is for the C allele. Note that the European results show the raw allele frequencies across cohorts, with the OR calculated from logistic regression that
includes covariates
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Gene-based association analysis. No genes were signiﬁcantly
associated with ALS from gene-based association analysis
implemented in fastBAT26 of Chinese data (based on Bonferroni
correction for ~18,000 autosomal genes, signiﬁcance declared at
2.8 × 10−6), but meta-analysed results (Supplementary Table 4)
identiﬁed multiple genes (reﬂecting LD and overlapping gene
boundaries) at the previously reported chromosome 5, 9, 14 and
17 GWAS loci. Two new loci on Chromosome 17 (17q12
and 17q21.2) were also signiﬁcant (minimum genic p= 3.3 × 10−7
and 1.2 × 10−7, respectively). The former locus was also supported
by summary statistic-based Mendelian randomization (SMR)
analysis27 that combines the disease–SNP association with gene
expression–SNP association results and has GW signiﬁcance
threshold of pSMR< 8.4 × 10−6) (Supplementary Fig. 7; Supple-
mentary Data 2), with most signiﬁcant association for GGNBP2
(European only pSMR= 4.6 × 10−6; meta-analysis pSMR= 9.8 × 10−6).
The two replication samples did not provide support for the
GGNBP2 SNP implicated from the SMR analysis (Supplementary
Table 5); larger sample sizes are needed to conﬁrm the association
and to provide evidence to exclude ZNHIT3 (pSMR= 3.1 × 10−5)
or MYO19 (pSMR= 2.2 × 10−4) as contributing to the association
in this region. Gene-set pathway analysis implemented in
MAGMA and applied to the Chinese/European meta-analysis
results did not ﬁnd any ALS signiﬁcant pathways that passed
multiple testing correction (Supplementary Table 6).
Discussion
In summary, using a cross-ethnic design we identify association
of the GPX3-TNIP1 locus with ALS. This locus was identiﬁed by
combining GWAS results from our Chinese data with the largest
European GWAS data7 and replicated in independent Australian
samples. In addition, GGNBP2 was identiﬁed using gene-based
analysis and SMR analysis, although further replication is needed
to conﬁrm this result. The discovery of a novel risk locus sig-
niﬁcantly advances our understanding of ALS aetiology.
Methods
Chinese ALS cases and controls. The samples comprised 1,324 ALS cases and
3,115 controls. ALS cases were recruited from the Department of Neurology, the
Peking University Third Hospital (Beijing, China) from 2003 to 2013. The cases
were diagnosed by a neurologist specializing in ALS using the revised El Escorial
criteria28. The controls are individuals who attended the Peking University Third
Hospital, Peking University Sixth Hospital or Shanghai Changzheng Hospital
(Shanghai) with no medical or family history of neurological disorders. All cases
and controls are of Chinese origin from Mainland China and provided written
informed consent for the study. The sample collections were approved by the ethics
committees at the respective hospitals12. The study is compliant with the Guidance
of the Ministry of Science and Technology (MOST) for the Review and Approval of
Human Genetic Resources. Analyses conducted at the University of Queensland
were approved by the University human research ethics committee.
Australian replication cohort 1. ALS cases were recruited from the Royal Brisbane
& Women’s Hospital (RBWH), Brisbane, Queensland and the Macquarie Uni-
versity Multidisciplinary Motor Neurone Disease Clinic29, New South Wales. The
cases (N= 159) were diagnosed using the revised El Escorial criteria10. The controls
are healthy individuals (N= 132), sourced from 4 different sites, RBWH (27
individuals), Neurology at Macquarie University, Sydney (25 individuals), the
Older Australian Twin Study (OATS)30 comprising 90 monozygotic (MZ) twin
pairs recruited in Brisbane (QIMR Berghofer Medical Research Institute (QIMR))
and Sydney (University of New South Wales (UNSW)) and Melbourne (University
of Melbourne (UM)). The OATS study recruits MZ twins aged ≥65 years and were
chosen for this study because the Discovery sample controls were younger than
Discovery sample cases. Twin pair data helped in quality control checks but only
one twin from each pair was used in analyses. The subjects provided written
informed consent for the study. The study was approved by the RBWH31, QIMR,
UNSW, UM, University of Queensland and Macquarie University Research Ethics
Committees.
Australian replication cohort 2. Patients and controls were ascertained from
Macquarie University Multidisciplinary Motor Neurone Disease and Neurology
Clinics, Sydney and from the Australian MND DNA bank. Patients were diagnosed
with deﬁnite or probable ALS according to the revised El Escorial criteria. Patients
with a family history for ALS were excluded. Control subjects were healthy
individuals free of neuromuscular diseases. DNA from 471 cases and 586 controls
were available for genotyping. The subjects provided written informed consent for
the study. The study was approved by Macquarie University Research Ethics
Committee.
DNA extraction. In the Chinese cohort, genomic DNA was extracted from whole
blood using the DNA Extraction Kit (Beijing Aide Lai Biotechnology Co. Ltd.,
Beijing, China). In the Australian replication cohorts, the majority of DNA was
extracted from fresh whole blood using manual extraction protocols, except for
90% (118 out of 131) of UNSW/UM control samples, where DNA was extracted
from frozen whole blood or lymphocytes using an automated puriﬁcation system,
Qiagen Autopure LS (Qiagen, Valencia, CA, USA).
Genome-wide association study. We performed GW genotyping in the discovery
cohort using the Illumina HumanOmni ZhongHua-8 v1.0 and v1.1 arrays. These
arrays contain 900,015 (v1.0) and 894,517 (v1.1) variants, respectively. Before
testing for the association between each variant and disease status, we carried out
quality control (QC) steps to identify and exclude poor quality samples and genetic
variants. We excluded individuals based on the following QC ﬁlters: (i) genotyping
call rate <99% (134 individuals); (ii) sex mismatch between genotype and clinical
information (6 individuals); (iii) ancestry outliers (6 SDs from HapMap-CHB
means of PC1 and PC2; 30 individuals); and (iv) duplicated or related individuals
(genetic relationship matrix >0.05; 195 individuals). We excluded genetic variants
based on the following criteria: (i) low genotype call rate <99%; (ii) MAF <1%;
(iii) deviation from Hardy–Weinberg equilibrium p < 10−6; and (iv) differential
missingness in genotypes between cases and controls (p < 10−6). After these QC
steps, 1,234 cases and 2,850 controls with genotypic information from 753,038
markers remained for the subsequent analyses.
We imputed unobserved genotypes into the 1000 Genomes Project Phase 1 v3
(all ethnicities) using samples and markers that passed QC. We implemented a
two-step process, i.e., haplotyping using HAPI-UR32 and imputation using
IMPUTE33. We imputed 38,033,906 SNPs, but after QC (i.e., excluding markers
with MAF <0.01, imputation quality score <0.80 and HWE p< 10−6), 6,613,544
SNPs were available for analysis.
Validation sample genotyping. The ﬁrst validation sample was genotyped on the
Illumina Human Core Exome Array. QC and imputation followed the same
pipeline as for the Chinese samples. After QC, 145 cases and 116 controls were
available for analysis. For the second validation sample, SNPs were genotyped
via Taqman assay such that the reaction mix included 1.0 μl of genomic DNA
(10 ng/μl), 0.25 μl Custom TaqMan genotyping assay 20× (Life Technologies),
2.5 μl TaqMan SNP genotyping MasterMix 2X (Life Technologies) and 6.25 μl
MilliQ. The thermocycler program included 30 s at 60 °C, 10 min at 95 °C, followed
by 40 cycles of 15 s at 95 °C and 1min at 60 °C and a ﬁnal step of 30 s at 60 °C.
Fluorescent signals were analysed on a Viia7 Real-Time PCR System and genotypes
were determined by allelic discrimination using the Viia7 Real-Time PCR System
Software (Life Technologies). Genotype calling rates were 94% for rs4958872
(LD r2= 1 proxy for rs10463311) and 91% for rs9906189. After QC, 431 cases and
567 controls were available for analysis.
Genetic association analysis. The association analysis between genetic variants
and disease was conducted using a linear mixed model framework implemented in
GCTA (mlma-loco)34. To compare the results, we also used a logistic regression
model by ﬁtting ﬁve principal components as covariates. Genomic inﬂation factor
was calculated as the median of Chi-square test statistics divided by its expected
value (0.455).
Gene-based analysis. To test for the association between a set of variants within a
gene (±50 kb) and ALS, we used GCTA-fastBAT26 with SNP association analysis
p values as input. This test complements SNP–disease association analysis,
identifying genes that may show evidence for independent associations that
individually have not achieved association signiﬁcance. For Chinese data analysis,
we used our own GWAS data as the reference to calculate LD and ARIC samples
(dbGAP accession phs000090.v1.p1) for the European sample.
Whole-genome estimation analysis. Genomic relationship matrix (GRM)
restricted maximum likelihood (GREML) analysis using GCTA19, 35, 36 was used to
estimate the total contribution of common genetic variants on the liability of ALS
or SNP-heritability. This analysis ﬁts all SNPs simultaneously in a mixed model
linear framework to estimate the proportion of variance in disease liability
explained by all SNPs. To avoid bias, for example, due to common environmental
factors, we excluded related individuals based on GRM values >0.05. Lifetime
disease risk of 0.002 was used in the conversion of the estimate to the liability
scale37 (compared to 0.0025 used in the European conversion, although the results
are robust to these choices). LD-score regression20 was applied to GWAS summary
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statistics as an alternative method to estimate the contribution of common genetic
variants to variation in the liability of ALS.
Genetic overlap analysis. We considered estimation of the genetic correlation
between ALS risk in Europeans and Chinese, using popcorn38 (the cross-ethnicity
LDscore regression method), but calculated39 that the relatively small sample size
for the Chinese cohort would generate an unacceptably large SE. Instead we used
polygenic risk scoring (PRS) to investigate the genetic relationship between ALS in
the two ethnicities. PRS were estimated for all Chinese cases and controls as the
sum of risk alleles weighted by the log OR of association estimated in the European
GWAS. Eight PRS were constructed for each individual using independent SNPs
(based on SNPs pruned (r2< 0.25 in 200-kb window) that are signiﬁcant at p value
thresholds of 0.001, 0.005, 0.01, 0.05, 0.10, 0.25, 0.5 and 1. We also constructed a
PRS using all SNPs without pruning for LD because of the difference in allele
frequencies and LD between ethnicities. Association between the case–control
status and PRS was evaluated by logistic regression. Binomial sign tests were also
used to evaluate evidence of overlap in signal between Chinese and European
association statistics.
Meta-analysis. Inverse variance meta-analysis was conducted between the largest
GWAS for ALS in European7 and our Chinese GWAS results using METAL40.
In silico functional analyses. To help interpret biological function of the
SNP– and gene–ALS associations, gene-set pathway analyses were performed using
MAGMA41; this method was selected based on results of a method comparison
study42. Gene-set pathway analyses aim to identify sets of biological pathways that
are relevant to disease based on a set of disease-associated variants42.We also
conducted SMR analysis27 that combines the GWAS summary statistics with gene
expression association results. Here we used gene expression from blood43 as this is
currently the largest gene expression quantitative trait loci data set. The SMR test
identiﬁes pleiotropic association of a variant that affects both the expression level of
a gene and the trait. The SMR-HEIDI test attempts to determine whether the effect
of the disease-associated gene on gene expression reﬂects a single causal variant,
thus prioritizing loci for functional follow-up studies.
Data availability. GWAS summary statistics results and gene expression data are
available from http://cnsgenomics.com/data/benyamin_et_al_2017_nc/
BenyaminEtAl_NatComm_Data.zip.
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